Asset Details
Do you wish to reserve the book?
Ankylosing Spondylitis and Rheumatoid Arthritis : Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ankylosing Spondylitis and Rheumatoid Arthritis : Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
Do you wish to request the book?
Ankylosing Spondylitis and Rheumatoid Arthritis : Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ankylosing Spondylitis and Rheumatoid Arthritis : Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
2014
Overview
The effects of the TNF-α blockers infliximab or etanercept on the levels of TNF-α, TNF-receptor 1 (TNF-R1), and TNF-receptor 2 (TNF-R2), as well as the levels of the inflammation markers CRP and IL-6, were measured in ankylosing spondylitis (AS) and rheumatoid arthritis (RA) patients receiving treatment with either compound. We found that RA patients tend to have higher levels of TNF-α than both healthy individuals and AS patients prior to treatment (P<0.05). We measured greatly increased levels of TNF-α in both the AS and RA etanercept patient groups during the course of treatment, while in the infliximab treated patients, the amount of TNF-α measured remained unchanged. Elevated TNF-α in the etanercept treated patients does not appear to be a significant risk factor for the spontaneous development of further autoimmune diseases in our study group. Increased levels of TNF-R1 were determined in both AS (P<0.05) and RA (P<0.001) patients when compared to healthy controls. In AS patients, the levels of TNF-R1 dropped significantly when treated with either infliximab (P<0.01) or etanercept (P<0.001). In contrast, the levels of this receptor remained unchanged in RA patients treated with either compound.
Publisher
Hindawi Puplishing Corporation,Hindawi Publishing Corporation
Subject
/ Aged
/ Antibodies, Monoclonal - administration & dosage
/ Antirheumatic Agents - administration & dosage
/ Arthritis, Rheumatoid - blood
/ Arthritis, Rheumatoid - drug therapy
/ Humans
/ Immunoglobulin G - administration & dosage
/ Male
/ Receptors, Tumor Necrosis Factor - administration & dosage
/ Receptors, Tumor Necrosis Factor, Type I - blood
/ Receptors, Tumor Necrosis Factor, Type II - blood
/ Spondylitis, Ankylosing - blood
